This integration marks an exciting step forward in our journey to build a best-in-class platform for providing private brand and contract manufacturing solutions to our North America customers,” — ...

Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S.

Vivos Therapeutics(NASDAQ:VVOS) reported second quarter 2025 results on August 20, 2025, marking a pivotal shift from its legacy dentist-focused model to a direct, patient-centric sleep center ...

Vivos Therapeutics shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding ...

Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance Treatment LITTLETON, Colo., July 01, 2025 (GLOBE ...

With over 80% of OSA cases in the United States undiagnosed and an estimated 80 million Americans affected, Vivos’ comprehensive portfolio of OSA treatments is poised to capture a significant share of ...

Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...

LITTLETON, Colo. - Vivos Therapeutics, Inc. (NASDAQ:VVOS), a small-cap medical device company with a market capitalization of $17.85 million, announced Thursday that a multicenter clinical trial ...

Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of ...

Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) ...

Symptoms of sleep-related breathing disorders decreased from 0.28 to 0.14, while snoring decreased by 58%. Vivos believes this breakthrough regulatory clearance represents a huge opportunity to ...